| Literature DB >> 27917862 |
Firouzeh Dehghan1, Rahman Soori1, Khadijeh Gholami2, Mitra Abolmaesoomi3, Ashril Yusof4, Sekaran Muniandy3, Sara Heidarzadeh, Parvin Farzanegi, Mohammad Ali Azarbayjani.
Abstract
The aim of this study was to investigate the responses of atherosclerosis plaque biomarkers to purslane seed consumption and aerobic training in women with T2D. 196 women with T2D were assigned into; (1) placebo (PL), (2) aerobic training+placebo (AT + PL), 3) purslane seeds (PS), aerobic training+purslane seeds (AT + PS). The training program and purslane seeds consumption (2.5 g lunch and 5 g dinner) were carried out for 16 weeks. The components of purslane seed were identified and quantified by GC-MS. Blood samples were withdrawn via venipuncture to examine blood glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL), cholesterol, triglycerides (TG), creatinine, urea, uric acid, NF-κB, GLP1, GLP1R, TIMP-1, MMP2, MMP9, CRP, CST3, and CTSS expressions. Blood glucose, LDL, cholesterol, TG, creatinine, urea, and uric acid levels in the (P), (AT), and (AT + PS) groups were significantly decreased compared to the pre-experimental levels or the placebo group, while HDL, significantly increased. Furthermore, the protein and mRNA levels of NF-κB, TIMP-1, MMP2 &9, CRP, CST3, and CTSS in the (P), (AT), (AT + PS) significantly decreased compared to pre-experimental or the placebo group, while level of GLP1 and GLP1-R increased drastically. Findings suggest that purslane seed consumption alongside exercising could improve atherosclerosis plaque biomarkers through synergistically mechanisms in T2D.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27917862 PMCID: PMC5137030 DOI: 10.1038/srep37819
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic illustration of some of the key pathological pathways that are involved in both type 2 diabetes and atherosclerosis.
Hyperglycemia, hyperlipidemia, hyperinsulinia, and hyperuricimia increase ROS generation through oxidative stress. ROS activates a number of stress sensitive kinase which mediates insulin resistance via activation of NF-κB and CRP. On the other hand, activation of NF-κB and CRP affect the structure of extracellular matrix and increase the activity of MMP and cathepsin S which are involved in atherosclerosis and diabetes. Exercise and purslane intake improve the regulation of biomarkers involved in the activation of these pathways. TG; triglycerides, LDL; Low-density lipoprotein, ROS; reactive oxygen species, NF-κB; nuclear factor kappa-light-chain-enhancer of activated B cells, CRP; C-reactive protein, MMPs; Matrix metalloproteinase, TIMP-1; metallopeptidase inhibitor 1.
Characteristics and demographics of the diabetics’ subjects.
| Placebo (PL) Mean ± SEM | Aerobic Training + Placebo (AT + PL) Mean ± SEM | Purslane Seeds (PS) Mean ± SEM | Aerobic Training + Purslane Seeds (AT + PS) Mean ± SEM | |
|---|---|---|---|---|
| Age, year | 50.17 ± 5.34 | 58.83 ± 6.79 | 52.33 ± 4.08 | 61.17 ± 4.88 |
| Height, cm | 160.67 ± 6.44 | 162.50 ± 6.53 | 159.17 ± 6.65 | 154.50 ± 10.60 |
| Weight, cm | 75.67 ± 9.44 | 79.50 ± 8.96 | 73.50 ± 6.65 | 70.83 ± 7.88 |
| BMI, Kg/m2 | 29.8 ± 6.4 | 29.5 ± 7.2 | 29.0 ± 5.0 | 29.9 ± 7.3 |
Composition of total components contents of purslane seeds.
| Peak # | Name | R.T. (s) | Area | Relative Amount (RA) | Mass |
|---|---|---|---|---|---|
| 1 | 2-Propanol, 1-[(1-methylethyl) amino]-3-[2-(2-propenyl) phenoxy]-(Alprenolol, or alfeprol, alpheprol) | 252.15 | 311449 | 0.04 | 249 |
| 2 | 4-Methylpiperidine-1-carboxylic acid, phenyl ester (acid amin3) | 485.35 | 6340394 | 0.81 | 219 |
| 3 | N-(1-Methoxycarbonyl-1-methylethyl)-4-methyl-2-aza-1,3-dioxane | 582.25 | 4477291 | 0.57 | 203 |
| 4 | Tetrahydropyran-4-ol, 2,2-dimethyl-4-[[(thiophen-2-ylmethyl) amino]methyl]- | 717.9 | 129487357 | 16.61 | 255 |
| 5 | 1,3-Oxathiolane, 2-[[(2-chloroethyl) thio]methyl]-2-methyl- | 736.3 | 388091 | 0.05 | 212 |
| 6 | Benzoic acid, 2-(2-isopropyl-5-methylphenoxymethyl)- | 853 | 6451312 | 0.83 | 284 |
| 7 | 29.82 Methyl dodecanoate | 1684.55 | 2410439 | 0.31 | 214 |
| 8 | n-Hexadecanoic acid (Palmitic acid) | 1731.6 | 61905629 | 7.94 | 256 |
| 9 | Decanamide, N-(2-hydroxyethyl)- | 1925.3 | 52686347 | 6.76 | 215 |
| 10 | 9,12-Octadecadienoic acid (Z,Z)- Linoleic acid (LA) | 1927.4 | 120792530 | 15.49 | 280 |
| 11 | 9-Hexadecenoic acid-(Palmitoleic acid) | 1933.25 | 93736575 | 12.02 | 254 |
| 12 | 9,12,15-Octadecatrien-1-ol, (Z,Z,Z)- | 1934.05 | 24934192 | 3.20 | 264 |
| 13 | S-[2-[N,N-Dimethylamino]ethyl]N,N-dimethylcarbamoyl thiocarbohydroximate | 2074.5 | 4196678 | 0.54 | 219 |
| 14 | Palmidrol | 2103.5 | 10489224 | 1.35 | 299 |
| 15 | 4-(7-Methoxy-7-methyloxepan-2-ylidene) butan-2-one | 2110.3 | 5920620 | 0.76 | 212 |
| 16 | 6-Methoxy-2-methyl-quinoline-3-carboxylic acid 2-dimethylamino-ethyl ester | 2240.95 | 16583058 | 2.13 | 288 |
| 17 | Glycerol 1-palmitate | 2292.1 | 24680340 | 3.17 | 330 |
| 18 | Z-5,17-Octadecadien-1-ol acetate | 2453.7 | 79862448 | 10.24 | 308 |
| 19 | 9,12,15-Octadecatrien-1-ol, (Z,Z,Z)- | 2460.85 | 29437987 | 3.78 | 264 |
| 20 | 3H-Imidazo[4,5-b]pyridine, 2-(2-ethylhexylsulfanyl)- | 2753 | 17494020 | 2.24 | 263 |
| 21 | beta-Sitosterol | 3004.8 | 87157789 | 11.18 | 414 |
Figure 2Chromatographic profile of purslane seed methanolic extract, the 21 known and unknown peaks components are identified.
Changes in the serum variables of diabetic subjects between 4 groups pre and post 16 weeks experiments.
| Variable | Stage | Placebo (PL) Mean ± SEM | Aerobic Training + Placebo (AT + PL) Mean ± SEM | Purslane Seeds (PS) Mean ± SEM | Aerobic Training + Purslane Seeds (AT + PS) Mean ± SEM |
|---|---|---|---|---|---|
| Glucose, mg/dL | Pre Post | 168.2 ± 18.1 | 164.8 ± 17.5 | 167.4 ± 14.1 | 167.6 ± 20.6 |
| 173.1 ± 19.7 | 147.3 ± 18.3 | 152.1 ± 11.9 | 140.1 ± 15.2 | ||
| LDL-C, mg/dL | Pre Post | 83.3 ± 8.6 | 87.1 ± 12.4 | 84.1 ± 14.2 | 86.3 ± 11.7 |
| 82.1 ± 19.7 | 75.5 ± 17.2 | 79.9 ± 12.6 | 72.8 ± 19.7 | ||
| HDL-C, mg/dL | Pre Post | 35.8 ± 4.9 | 36.7 ± 8.3 | 35.3 ± 7.2 | 34.9 ± 3.7 |
| 33.6 ± 9.1 | 39.8 ± 10.3 | 39.2 ± 6.9 | 46.7 ± 7.4 | ||
| Cholesterol, mg/dL | Pre Post | 197.2 ± 22.4 | 198.5 ± 26.1 | 196.9 ± 22.6 | 198.7 ± 24.8 |
| 209.2 ± 20.1 | 169.7 ± 14.8 | 172.3 ± 19.3 | 155.2 ± 16.4 | ||
| TG, mg/dL | Pre Post | 183.1 ± 26.3 | 182.8 ± 21.7 | 183.6 ± 27.2 | 183.1 ± 23.8 |
| 182.9 ± 24.7 | 152.7 ± 29.2 | 159.3 ± 22.0 | 142.2 ± 21.5 | ||
| Creatinine, mg/dL | Pre Post | 1.43 ± 0.04 | 1.41 ± 0.05 | 1.40 ± 0.05 | 1.41 ± 0.03 |
| 1.43 ± 0.02 | 0.81 ± 0.06 | 0.88 ± 0.06 | 0.42 ± 0.07 | ||
| Urea, mg/dL | Pre Post | 19.31 ± 1.19 | 18.99 ± 1.04 | 18.86 ± 0.82 | 19.01 ± 0.63 |
| 19.31 ± 1.11 | 14.21 ± 0.98 | 14.42 ± 0.07 | 10.62 ± 0.98 | ||
| Uric Acid mg/dL | Pre Post | 4.65 ± 0.15 | 4.82 ± 0.18 | 4.59 ± 0.16 | 4.71 ± 0.15 |
| 4.66 ± 0.42 | 3.38 ± 0.21 | 3.11 ± 0.14 | 2.39 ± 0.23 |
*Denote significant differences from pre-test.
†Denote significant differences from Placebo group.
#Denote significant differences from Aerobic Training+ Placebo.
ΩDenote significant differences from Purslane Seeds group.
p < 0.05 as compared to pre-test, Placebo, Aerobic Training+ Placebo, and Purslane Seeds groups.
Changes in the Serum biomarkers concentration diabetic subjects between 4 groups pre and post 16 weeks experiments.
| Variable | Stage | Placebo (PL) Mean ± SEM | Aerobic Training+ Placebo (AT + PL) Mean ± SEM | Purslane Seeds (PS) Mean ± SEM | Aerobic Training+Purslane Seeds (AT + PS) Mean ± SEM |
|---|---|---|---|---|---|
| NF-κB1, ng/mL | Pre Post | 8.74 ± 0.7 | 8.87 ± 0.5 | 8.52 ± 0.5 | 8.79 ± 0.6 |
| 8.69 ± 0.2 | 6.7 ± 0.3 | 6.5 ± 0.4 | 5.3 ± 0.4 | ||
| GLP1, ng/mL | Pre Post | 5.44 ± 0.3 | 4.38 ± 0.6 | 3.82 ± 0.3 | 3.43 ± 0.3 |
| 5.55 ± 0.4 | 5.78 ± 0.3 | 4.93 ± 0.6 | 5.77 ± 0.7 | ||
| GLP1-R, ng/mL | Pre Post | 0.56 ± 0.012 | 0.52 ± 0.016 | 0.48 ± 0.017 | 0.49 ± 0.011 |
| 0.59 ± 0.018 | 0.69 ± 0.013 | 0.67 ± 0.015 | 0.71 ± 0.014 | ||
| TIMP-1, ng/mL | Pre Post | 10.72 ± 0.56 | 10.47 ± 0.47 | 10.22 ± 0.68 | 10.86 ± 0.87 |
| 10.69 ± 0.6 | 6.98 ± 0.95 | 7.84 ± 0.44 | 5.12 ± 0.65 | ||
| MMP2, ng/mL | Pre Post | 0.88 ± 0.02 | 0.87 ± 0.03 | 0.88 ± 0.02 | 0.86 ± 0.02 |
| 0.87 ± 0.03 | 0.70 ± 0.04 | 0.67 ± 0.03 | 0.55 ± 0.04 | ||
| MMP9, ng/mL | Pre Post | 1.62 ± 0.05 | 1.59 ± 0.07 | 1.58 ± 0.08 | 1.60 ± 0.07 |
| 1.61 ± 0.04 | 1.08 ± 0.22 | 1.05 ± 0.15 | 0.55 ± 0.19 | ||
| CRP, mg/mL | Pre Post | 8.72 ± 0.4 | 7.91 ± 0.6 | 7.85 ± 0.6 | 8.56 ± 0.7 |
| 8.83 ± 0.5 | 6.1 ± 0.3 | 6.2 ± 0.1 | 5.1 ± 0.3 | ||
| CST3, ng/mL | Pre Post | 35.13 ± 4.32 | 35.33 ± 3.52 | 34.71 ± 4.61 | 34.51 ± 3.22 |
| 35.75 ± 3.25 | 26.25 ± 3.95 | 25.98 ± 2.44 | 20.09 ± 3.65 | ||
| CTSS, ng/mL | Pre Post | 0.77 ± 0.02 | 0.76 ± 0.03 | 0.79 ± 0.06 | 0.79 ± 0.03 |
| 0.77 ± 0.02 | 0.64 ± 0.05 | 0.61 ± 0.02 | 0.29 ± 0.02 |
$Denote significant differences from pre-test.
βDenote significant differences from Placebo group.
€Denote significant differences from Aerobic Training+ Placebo.
£Denote significant differences from Purslane Seeds group.
p < 0.05 as compared to pre-test, Placebo, Aerobic Training+ Placebo, and Purslane Seeds groups.
Figure 3Blood CRP, NF-κB, GPL-1, and GPL1-R, mRNA expression and activity at pre or post treatment in diabetic type 2 women. Data were expressed as mean ± SEM.
PL; Placebo, PL + A; Placebo + Aerobic, PS; Purslane Seed, and A + PS; Aerobic + Purslane Seed. *p < 0.05 as compared to Placebo group.
Figure 4Blood MMP-2, MMP-9, and TMP-1 mRNA expression and activity at pre or post treatment in diabetic type 2 women. Data were expressed as mean ± SEM.
PL; Placebo, PL + A; Placebo + Aerobic, PS; Purslane Seed, and A + PS; Aerobic + Purslane Seed. *p < 0.05 as compared to Placebo group.
Figure 5Blood CST3 and CTSS mRNA expression and activity at pre or post treatment in diabetic type 2 women.
Data were expressed as mean ± SEM. PL; Placebo, PL + A; Placebo + Aerobic, PS; Purslane Seed, and A + PS; Aerobic + Purslane Seed. *p < 0.05 as compared to Placebo group.